AI upptäcker tumörsjukdom – via röstinspelning

En kort röstinspelning tillsammans med ansiktsbilder – i bägge fallen analyserade med en AI-algoritm – kan göra det möjligt att upptäcka den sällsynta tumörsjuk...

Samuel Lagercrantz: We are currently seeing medical breakthroughs in these areas

Samuel Lagercrantz, Editor in Chief of Life Science Sweden, lists three medical fields in which we are currently seeing major breakthroughs and two fields in wh...

Radioaktivt spårämne ska visa effekt av läkemedel mot tarmsjukdom

En radioaktiv markör som utvecklats av Astra Zeneca och Karolinska institutet kan spela en stor roll för patienter med Crohns sjukdom. Det menar Maria Belvisi, Astra Zeneca.

Här är människorna bakom de utpekade rovförlagen

I en artikelserie har Life Science Sweden rapporterat om rovtidskrifter och om tidskriftskapare. Men vilka är människorna bakom? Spåren leder till framgångsrika...

MedVasc and Scientific Solutions join forces to streamline FDA 510(k) regulatory process

MedVasc, an exciting MedTech startup company, and Scientific Solutions, a renowned consulting firm within Life Science, are pleased to announce a strategic part...

Meeting with focus on South Korea and Japan’s life sciences

Large, complex and exciting – this is how Britta Stenson, Business Sweden, describes the life science markets of Japan and South Korea, which took centre stage ...

Optimism på Xspray efter uppgörelse i patenttvist

En uppgörelse uppges ha nåtts i patenttvisten mellan svenska forskningsbolaget Xspray Pharma och läkemedelsjätten Bristol Myers Squibb (BMS) om cancerkandidaten Dasynoc.

Erfaren medtechledare tar över klubban i Realheart

Medtechbolaget Realheart, som utvecklar ett artificiellt hjärta, har utsett Magnus Öhman till arbetande styrelseordförande.

Eli Lilly to build a USD 2.5-billion plant in Germany

US-based Eli Lilly is planning a huge investment of USD 2.5 billion, equivalent to around SEK 26.5 billion, in a new production facility in Alzey, Germany.

Study: Vaccination linked to lower risk of post-COVID

The risk of developing post-COVID after a COVID infection was reduced in vaccinated people, according to a new study from the University of Gothenburg.

Suing the company – for NOT developing a new HIV drug

Was Gilead putting a steady flow of profits from its cash cow ahead of developing a new and safer drug? According to a large number of US HIV patients in a lega...

The Swedish Life Science Office: “We lost in both coordination and manpower”

Since the turn of the year, the Swedish government’s life science office has operated at a lower capacity. Life Science Sweden has spoken to Pontus Holm, Depart...

Tirzepatide approved for obesity by the FDA – to be branded as Zepbound

Diabetes drug tirzepatide has now also been approved in the US for treating obesity.

Improve your secondary battery manufacturing

SMC provides a large portfolio of products specially designed for secondary battery industry.

Merrill Brink International

MetaSafe AB

Mikrolab Stockholm AB

Minerva Sverige AB

Monocl AB

Montex AB

Moveup Consulting AB

N4 Teknik AB

NNE Pharmaplan AB

Nordic Life Science Corporate Finance AB